TG003: Selective Clk Family Kinase Inhibitor for Alternative Splicing Modulation

Executive Summary: TG003 is a potent and selective inhibitor targeting the Cdc2-like kinase (Clk) family, especially Clk1 and Clk4, with nanomolar IC50 values (20 nM and 15 nM, respectively), and also inhibits Clk2 and casein kinase 1 (CK1) at higher concentrations [APExBIO]. It competitively blocks ATP binding to Clk1 with a Ki of 0.01 μM, suppressing phosphorylation of serine/arginine-rich (SR) proteins and modulating alternative mRNA splicing [Jiang et al., 2024]. TG003 reversibly inhibits SR protein phosphorylation in cell models and alters nuclear speckle localization, impacting splicing factor SF2/ASF [APExBIO]. In animal studies, it affects in vivo splicing patterns and is under investigation for exon-skipping therapy in Duchenne muscular dystrophy models [Jiang et al., 2024]. TG003 is provided by APExBIO (SKU B1431) and is soluble in DMSO and ethanol, supporting flexible laboratory workflows [APExBIO].

Biological Rationale

Cdc2-like kinases (Clks) are serine/threonine kinases essential for mRNA splicing regulation. They phosphorylate serine/arginine-rich (SR) proteins, which control splice site selection during pre-mRNA processing. Dysregulation of Clk activity is linked to disease states, including oncogenesis and neurodegeneration [Jiang et al., 2024]. Clk2, in particular, is upregulated in ovarian cancer and contributes to platinum resistance by enhancing DNA repair via BRCA1 phosphorylation. Targeted inhibition of Clks with small molecules like TG003 enables researchers to modulate splicing and investigate disease mechanisms.

Mechanism of Action of TG003

TG003 acts as a competitive ATP-binding inhibitor of Clk family kinases. The compound binds directly to the ATP pocket of Clk1, Clk2, and Clk4, with Ki values of 0.01 μM (Clk1) and low nanomolar IC50s for Clk1 (20 nM) and Clk4 (15 nM) [APExBIO]. It also inhibits Clk2 (IC50: 200 nM) and has limited activity on Clk3 (>10 μM). At cellular levels, TG003 effectively suppresses Clk1-mediated phosphorylation of splicing factor SF2/ASF, leading to altered alternative splicing events such as β-globin pre-mRNA splicing. The inhibition is reversible, and TG003 can modify nuclear speckle localization of Clk1, impacting SR protein phosphorylation dynamics. Additionally, TG003 inhibits casein kinase 1 (CK1) activity, although with less selectivity. These mechanisms allow TG003 to serve as a chemical probe for dissecting the Clk-mediated phosphorylation pathway and its role in splice site selection research [Related Article].

Evidence & Benchmarks

• TG003 inhibits Clk1 in vitro with an IC50 of 20 nM under standardized kinase assay conditions (25°C, ATP 100 μM, 30 min incubation) (APExBIO).
• Clk2 inhibition by TG003 exhibits an IC50 of 200 nM, supporting selectivity but requiring higher concentrations for full effect (Jiang et al., 2024).
• TG003 modulates alternative splicing in vivo, rescuing developmental abnormalities in Xenopus laevis embryos induced by Clk overexpression (APExBIO).
• In platinum-resistant ovarian cancer models, Clk2 inhibition reduces BRCA1 (Ser1423) phosphorylation, impairing DNA damage repair and sensitizing tumors to platinum therapy (Jiang et al., 2024).
• TG003 promotes exon skipping in dystrophin exon 31, enabling therapeutic investigation in Duchenne muscular dystrophy (DMD) models (APExBIO).
• Reversible inhibition of SR protein phosphorylation is demonstrated in HeLa and other mammalian cell lines at 10 μM TG003 in DMSO (APExBIO).

For a complementary overview of TG003’s use in precision splicing and platinum resistance models, see this recent review—this article extends the mechanistic detail and provides updated benchmarks for translational workflows.

Applications, Limits & Misconceptions

TG003 is used for mechanistic studies of alternative splicing, cancer research targeting Clk2, and preclinical exon-skipping therapy development. Its high selectivity for Clk1/Clk4 makes it suitable for dissecting specific phosphorylation pathways in cell and animal models. TG003’s modulation of splice site selection is leveraged in disease modeling, including platinum-resistant ovarian cancer and neuromuscular disorders. The compound also serves as a benchmark inhibitor in kinase selectivity panels and for validating splicing modulation workflows. For translational research strategies and integration in disease models, see this in-depth guide—the current article clarifies solubility, dosing, and workflow integration specifics.

Common Pitfalls or Misconceptions

• Limited efficacy on Clk3: TG003 has poor activity against Clk3 (IC50 >10 μM); it is not a universal Clk inhibitor.
• Solubility constraints: TG003 is insoluble in water and must be dissolved in DMSO or ethanol (≥12.45 mg/mL and ≥14.67 mg/mL, respectively, with sonication).
• Short-term solution stability: TG003 solutions are recommended for immediate or short-term use due to potential degradation at room temperature.
• Cell line and species specificity: Effects on alternative splicing may vary across cell types and animal models; dosing and response must be empirically validated.
• Non-specific kinase inhibition at high concentrations: At concentrations above 10 μM, off-target kinase inhibition (e.g., CK1) may occur.

Workflow Integration & Parameters

TG003 is supplied as a solid by APExBIO (B1431, official product page). For in vitro cell studies, TG003 is typically applied at 10 μM in DMSO; for animal work, a suspension of 30 mg/kg in vehicle (DMSO, Solutol, Tween-80, saline) is administered subcutaneously. Stock solutions should be freshly prepared and stored at -20°C. Solubility varies with solvent and may require ultrasonic treatment. For comprehensive workflow strategies, including advanced splicing assays and disease modeling, consult this systems-level perspective—the present article updates on dosing optimization and vehicle compatibility.

Conclusion & Outlook

TG003, a highly selective Clk family kinase inhibitor from APExBIO, is a validated research tool for dissecting splicing regulation and exploring translational pathways in cancer and neuromuscular disease. Its mechanistic specificity, robust benchmarks, and integration in platinum resistance and exon-skipping models make it a key asset for molecular biology and therapeutic development. Ongoing studies will continue to define its full translational potential and workflow best practices.